Viking Therapeutics (VKTX) Competitors $30.19 +2.68 (+9.74%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$30.35 +0.16 (+0.52%) As of 07/8/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VKTX vs. MDGL, LLY, QGEN, MRNA, VTRS, ASND, BPMC, BBIO, VRNA, and ROIVShould you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Madrigal Pharmaceuticals (MDGL), Eli Lilly and Company (LLY), Qiagen (QGEN), Moderna (MRNA), Viatris (VTRS), Ascendis Pharma A/S (ASND), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), and Roivant Sciences (ROIV). These companies are all part of the "medical" sector. Viking Therapeutics vs. Its Competitors Madrigal Pharmaceuticals Eli Lilly and Company Qiagen Moderna Viatris Ascendis Pharma A/S Blueprint Medicines BridgeBio Pharma Verona Pharma PLC American Depositary Share Roivant Sciences Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership. Is MDGL or VKTX more profitable? Viking Therapeutics has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -123.38%. Viking Therapeutics' return on equity of -14.41% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Madrigal Pharmaceuticals-123.38% -50.54% -37.19% Viking Therapeutics N/A -14.41%-14.02% Does the media prefer MDGL or VKTX? In the previous week, Viking Therapeutics had 12 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 15 mentions for Viking Therapeutics and 3 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.98 beat Viking Therapeutics' score of 0.44 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viking Therapeutics 7 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend MDGL or VKTX? Madrigal Pharmaceuticals currently has a consensus target price of $420.63, suggesting a potential upside of 46.29%. Viking Therapeutics has a consensus target price of $87.15, suggesting a potential upside of 188.68%. Given Viking Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Madrigal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Viking Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has more risk & volatility, MDGL or VKTX? Madrigal Pharmaceuticals has a beta of -1.05, indicating that its share price is 205% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.62, indicating that its share price is 38% less volatile than the S&P 500. Which has stronger earnings & valuation, MDGL or VKTX? Viking Therapeutics has lower revenue, but higher earnings than Madrigal Pharmaceuticals. Viking Therapeutics is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMadrigal Pharmaceuticals$180.13M35.44-$465.89M-$18.05-15.93Viking TherapeuticsN/AN/A-$109.96M-$1.15-26.25 Do insiders & institutionals hold more shares of MDGL or VKTX? 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are owned by institutional investors. 21.5% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 4.1% of Viking Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryViking Therapeutics beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Viking Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VKTX vs. The Competition Export to ExcelMetricViking TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.09B$2.88B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.06%P/E Ratio-26.2520.8027.0020.10Price / SalesN/A286.98435.75120.29Price / CashN/A41.1936.8257.86Price / Book3.827.487.985.56Net Income-$109.96M-$55.04M$3.16B$248.40M7 Day Performance8.91%2.44%2.41%4.67%1 Month Performance9.50%1.90%2.19%6.64%1 Year Performance-44.25%4.35%33.82%21.31% Viking Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VKTXViking Therapeutics3.8522 of 5 stars$30.19+9.7%$87.15+188.7%-40.8%$3.09BN/A-26.2520MDGLMadrigal Pharmaceuticals4.0737 of 5 stars$305.20+1.5%$420.63+37.8%-1.1%$6.78B$317.38M-16.9190LLYEli Lilly and Company4.9823 of 5 stars$777.88+0.3%$1,011.61+30.0%-15.3%$737.23B$45.04B63.2947,000Trending NewsOptions VolumeQGENQiagen3.8827 of 5 stars$48.08+0.6%$49.40+2.7%+22.3%$10.69B$1.98B120.555,765Dividend AnnouncementMRNAModerna4.3762 of 5 stars$27.54+1.4%$46.61+69.2%-72.1%$10.65B$3.24B-3.155,800VTRSViatris2.6564 of 5 stars$8.95-0.7%$10.40+16.2%-12.7%$10.50B$14.74B-2.8232,000ASNDAscendis Pharma A/S3.5977 of 5 stars$171.21-0.6%$220.67+28.9%+23.2%$10.47B$393.54M-27.261,017BPMCBlueprint Medicines1.5043 of 5 stars$128.15+0.0%$128.06-0.1%+10.4%$8.28B$562.12M-51.88640Insider TradeBBIOBridgeBio Pharma4.6665 of 5 stars$43.14-3.8%$58.85+36.4%+65.2%$8.19B$221.90M-12.22400VRNAVerona Pharma PLC American Depositary Share2.6057 of 5 stars$94.51+0.7%$101.10+7.0%+410.6%$8.05B$42.28M-47.2630Positive NewsROIVRoivant Sciences1.5177 of 5 stars$11.28-1.0%$17.50+55.1%+1.3%$7.67B$29.05M-45.12860 Related Companies and Tools Related Companies Madrigal Pharmaceuticals Competitors Eli Lilly and Company Competitors Qiagen Competitors Moderna Competitors Viatris Competitors Ascendis Pharma A/S Competitors Blueprint Medicines Competitors BridgeBio Pharma Competitors Verona Pharma PLC American Depositary Share Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VKTX) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viking Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viking Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
